480 A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6

480 A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6

Bibliographic Details
Main Authors: Susanna Ulahannan, Manish Patel, Gerald Falchook, David Spigel, Babar Bashir, Christine Duffy, Daniela Maier, Hisaya Azuma
Format: Article
Language:English
Published: BMJ Publishing Group 2021-11-01
Series:Journal for ImmunoTherapy of Cancer

Similar Items